Fremanezumab

GREENSHIELD ADMINISTRATION RELEASES 2023 DRUG TRENDS REPORT: THE INTRODUCTION OF NEW THERAPIES INCREASE UTILIZATION RATES

Retrieved on: 
Jeudi, octobre 19, 2023
Patient, Lisdexamfetamine, Colitis, Psoriasis, Galcanezumab, Health, Therapy, Social skills, Prevalence, Elijah Cummings Lower Drug Costs Now Act, Migraine, Methylphenidate, Rheumatoid arthritis, RA, Fremanezumab, Crohn's disease, Growth, Disease, Asthma, Pharmacy, Diabetes, Eye, Case management, Calcitonin gene-related peptide, COPD, ADHD, Appetite, Mental health, Pharmaceutical industry, Dietary supplement, Health insurance, Iain Greenshields, Semaglutide

Today, GreenShield introduces its 2023 GreenShield Administration Drug Trends Report , revealing key insights surrounding three main therapeutic categories that go beyond Ozempic.

Key Points: 
  • Today, GreenShield introduces its 2023 GreenShield Administration Drug Trends Report , revealing key insights surrounding three main therapeutic categories that go beyond Ozempic.
  • "In the ever-changing world of healthcare, GreenShield's 2023 Administration Drug Trends Report reveals a compelling narrative, with an overall rise in utilization rates - driven by new therapies and changes in how plan members approach their health," said Mark Rolnick, Executive Vice President, Head of GreenShield Administration.
  • This year's report provides data based on +32 million claims from over two million drug claimants processed by GreenShield Administration this year.
  • Beyond its annual Drug Trends report, GreenShield Administration unlocks better health for all through integrated health and benefits solutions for more than 6 million Canadians from coast-to-coast.

At Fifteen Months Post-Launch, AbbVie's Qulipta Outperforms Pfizer's Nurtec ODT on Perceived Overall Efficacy in the Preventive Migraine Space, According to Spherix Global Insights

Retrieved on: 
Jeudi, mars 16, 2023
Fremanezumab, NASA RealWorld-InWorld Engineering Design Challenge, Anticonvulsant, Migraine, Lundbeck, Teva, Eli Lilly and Company, Galcanezumab, Attention, Launch, Neurology, Parity, Topiramate, Tonix Pharmaceuticals, AbbVie, Physician, Safety, RealTime, Pharmaceutical industry, Erenumab, Atogepant, Pfizer

EXTON, Pa., March 16, 2023 /PRNewswire/ -- Spherix Global Insights recently released data from their Launch Dynamix™: Qulipta for Migraine Prevention (US) deep dive study tracking the launch of AbbVie's Qulipta for the preventive treatment of episodic migraines. At fifteen months post-launch, analysis reveals that AbbVie's brand has made significant strides over the course of their entry on prescriber perceptions, including increasingly favorable rating for Qulipta awareness, familiarity, use, satisfaction, likelihood to recommend, and the brand's risk/benefit and cost/benefit ratios.

Key Points: 
  • Use of Qulipta as a preventive migraine treatment still trails Nurtec ODT, but future projections have the brands' use on par.
  • Furthermore, the past several months have revealed quite a surge for Qulipta preference in a head-to-head comparison with Nurtec ODT among surveyed neurologists and migraine specialists (n=74).
  • Specifically, Qulipta is viewed as performing better than Nurtec ODT when it comes to overall efficacy and safety, and most notably, favorable dosing schedule.
  • As one migraine treater noted,
    "Qulipta is a good choice and the patient was more comfortable with Qulipta than the Nurtec dosing.

Studies Show Effectiveness of AJOVY®▼ (fremanezumab) for Treatment of Migraine in Patients With Co-morbid Depression

Retrieved on: 
Jeudi, septembre 8, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Mental Health, COVID-19, Safety, Migraine, Grammatical mood, Depression, Vall, Pain, Population, Adult, Travel, Comorbidity, Biosimilar, Private Securities Litigation Reform Act, Department, European, Teva, Anxiety, Teaching hospital, Quality of life, Investment, Neuroscience, Lists of diseases, TASE, American Academy of Neurology, UNITE, NYSE, American Academy, Psychiatry, Behavioural sciences, Department of Neurology, Xuanwu hospital, FOCUS, Compliance, Failure, TEVA, Industry, Annual report, Forward-looking statement, Pharmaceutical industry, Hospital, Research, Fremanezumab, Patient

I believe that we need to move towards more personalised treatment decisions that are tailored to the patients profile and co-morbidities.

Key Points: 
  • I believe that we need to move towards more personalised treatment decisions that are tailored to the patients profile and co-morbidities.
  • As depression and anxiety are commonly associated with migraine, it will be very important for treatments to demonstrate efficacy and safety in migraine patients with these particular co-morbidities.
  • Anxiety and depression associated with migraine: Influence on migraine subjects' disability and quality of life, and acute migraine management.
  • A Phase 4 Study of Fremanezumab for Preventive Migraine Treatment in Patients With Major Depressive Disorder: Baseline Patient Characteristics in UNITE.

Biohaven's Nurtec ODT and AbbVie's Qulipta Emerging as the Top Two Contenders in the Preventive Migraine Space, According to Spherix Global Insights

Retrieved on: 
Vendredi, juin 10, 2022
Eli Lilly and Company, Amgen, Teva, Awareness, Pfizer, Ophthalmology, Neurology, AbbVie, Acquisition, Fremanezumab, Gastroenterology, Mark (given name), Galcanezumab, Nephrology, Dermatology, Benchmarking, Safety, Pharmaceutical industry, Migraine, Growth

EXTON, Pa., June 10, 2022 /PRNewswire/ -- According to the latest deep dive report included in Spherix's Launch Dynamix™: Qulipta for Migraine Prevention (US) service, surveyed neurologists and migraine specialists report high satisfaction with AbbVie's Qulipta across several performance metrics early in the product's launch. However, Biohaven's Nurtec ODT is reportedly up to par with Qulipta on most attributes, including overall efficacy, safety, tolerability, and favorable dosing schedule.

Key Points: 
  • However, Biohaven's Nurtec ODT is reportedly up to par with Qulipta on most attributes, including overall efficacy, safety, tolerability, and favorable dosing schedule.
  • In fact, Nurtec ODT outperforms Qulipta on ease of market access and breadth of approved indications.
  • Respondents anticipate robust six-month projected market share for both products, with a 50% increase for Nurtec ODT and more than 250% for Qulipta.
  • The EU5 market will be exciting to watch with Biohaven's Vydura (Nurtec ODT in the US) recently gaining approval and Qulipta expected to be approved sometime in 2023.

Robust Uptake of AbbVie's Qulipta Turns Up the Pressure for Amgen, Eli Lilly, and Teva in the Prevention Segment of the Migraine Market, Spherix Reports

Retrieved on: 
Mardi, février 8, 2022
Eli Lilly and Company, Neurology, Growth, Migraine, Allergan, Galcanezumab, HCP, Nephrology, US, Amgen, Patient, AbbVie, CGRP, Teva, Physician, SC, Benchmarking, Fine chemical, Pharmaceutical industry, Fremanezumab

The first of six quarterly deep dive reports included in Spherix's Launch Dynamix: Qulipta (AbbVie) for Migraine Prevention (US) service collected the responses of 86 U.S. neurologists and migraine specialists three months post launch.

Key Points: 
  • The first of six quarterly deep dive reports included in Spherix's Launch Dynamix: Qulipta (AbbVie) for Migraine Prevention (US) service collected the responses of 86 U.S. neurologists and migraine specialists three months post launch.
  • Positive clinical experiences with the oral gepants within the prevention segment foretells competitive headwinds for Aimovig, Eli Lilly's Emgality, and Teva's Ajovy.
  • Two-thirds of physicians agree that data supporting the efficacy of Qulipta for the prevention of chronic migraine would greatly increase their use of the brand.
  • Spherix will continue to assess Qulipta perceptions and related prescribing patterns via their ongoing Launch Dynamix, RealTime Dynamix, and RealWorld Dynamix services.

Teva Announces Ministry of Health, Labour and Welfare Approves AJOVY® (fremanezumab) Injection in Japan for the Preventive Treatment of Migraine in Adults

Retrieved on: 
Mercredi, juin 23, 2021
Health, Other Science, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Hormones, Monoclonal antibodies, Branches of biology, Calcitonin gene-related peptide receptor antagonists, Endocrine system, Calcitonin gene-related peptide, Neuropeptides, Migraine, Teva Pharmaceuticals, Fremanezumab, Calcitonin, AJOVY (fremanezumab-vfrm) injection, Teva, AJOVY (FREMANEZUMAB-VFRM) INJECTION, TEVA

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the Ministry of Health, Labour and Welfare (MHLW) has approved the use of AJOVY (fremanezumab) injection for the preventive treatment of migraine in adults in Japan.

Key Points: 
  • Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the Ministry of Health, Labour and Welfare (MHLW) has approved the use of AJOVY (fremanezumab) injection for the preventive treatment of migraine in adults in Japan.
  • Driven by our global mission to improve patients lives, we are pleased to offer this new treatment option to people living with migraine in Japan.
  • In 2020, the two companies announced outcomes from two pivotal studies of AJOVY in people living with episodic and chronic migraine in Japan.
  • AJOVY is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults.

Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults

Retrieved on: 
Jeudi, avril 8, 2021
Pharmacology, Medical equipment, Life sciences, Health sciences, Monoclonal antibodies, Teva Pharmaceuticals, Calcitonin gene-related peptide, Fremanezumab, Autoinjector, Migraine, Subcutaneous, Teva

AJOVY is the first and only subcutaneous anti-CGRP treatment with both quarterly (every three months) and monthly dosing options using either the autoinjector or prefilled syringe for the preventive treatment of migraine in adults.

Key Points: 
  • AJOVY is the first and only subcutaneous anti-CGRP treatment with both quarterly (every three months) and monthly dosing options using either the autoinjector or prefilled syringe for the preventive treatment of migraine in adults.
  • AJOVY is supported by the AJOVY Teva Support Solutions (AJOVY TSS) Patient Support Program, whose services include reimbursement navigation, bridging/copay coverage, and injection training.
  • MONTRAL, April 8, 2021 /CNW/ - Teva Canada, a subsidiary of Teva Pharmaceutical Industries Ltd., today announced the launch and availability of a new autoinjector for AJOVY(fremanezumab).
  • AJOVYis a subcutaneous injection for the preventive treatment of migraine in adults who have at least four migraine days per month.

Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults

Retrieved on: 
Jeudi, avril 8, 2021
Other Consumer, Medical devices, Insurance, Clinical trials, Professional services, Biotechnology, Managed care, General Health, Consumer, Health, Pharmaceutical companies, Monoclonal antibodies, Teva Pharmaceuticals, Life sciences, Fremanezumab, Pharmacology, Teva Canada, Teva, Migraine, Autoinjector, AJOVY, Teva Canada, Teva Pharmaceutical Industries Ltd.

Teva Canada, a subsidiary of Teva Pharmaceutical Industries Ltd., today announced the launch and availability of a new autoinjector for AJOVY (fremanezumab).

Key Points: 
  • Teva Canada, a subsidiary of Teva Pharmaceutical Industries Ltd., today announced the launch and availability of a new autoinjector for AJOVY (fremanezumab).
  • AJOVY is a subcutaneous injection for the preventive treatment of migraine in adults who have at least four migraine days per month.
  • View the full release here: https://www.businesswire.com/news/home/20210408005437/en/
    Teva Canada announces new autoinjector for AJOVY (fremanezumab) for the preventive treatment of migraine in adults.
  • I see AJOVY as a complete package of care, with injection training and other support delivered through our AJOVY Teva Support Solutions (AJOVY TSS) Patient Support Program.

New Study Published in Cephalalgia Identifies Mechanistic Differences Among CGRP Migraine Treatments

Retrieved on: 
Vendredi, février 26, 2021
Health, Clinical trials, General Health, Research, Pharmaceutical, Science, Medical specialties, Branches of biology, Clinical medicine, Monoclonal antibodies, Immunology, Calcitonin gene-related peptide, Neuropeptides, Calcitonin gene-related peptide receptor antagonists, Fremanezumab, Migraine, CALCRL, Calcitonin

This study demonstrated marked differences in the mechanism of blocking the calcitonin gene-related peptide (CGRP) ligand versus the CGRP receptor.

Key Points: 
  • This study demonstrated marked differences in the mechanism of blocking the calcitonin gene-related peptide (CGRP) ligand versus the CGRP receptor.
  • For instance, fremanezumab in particular, as a monoclonal antibody against the CGRP ligand, is targeted and specific in its mechanism.
  • AJOVY (fremanezumab-vfrm) injection is a fully humanized IgG2A monoclonal antibody that specifically and solely targets CGRP, a key neuropeptide involved in the pathophysiology of migraine.
  • Clinical implications of these findings are unknown, but the in vitro studies provide insights into potential mechanistic differences.

Teva Announces New Analysis of Consistency in Migraine Days Over the Course of a Dosing Regimen for AJOVY® (fremanezumab-vfrm) Injection Published in Headache

Retrieved on: 
Mercredi, octobre 7, 2020
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Monoclonal antibodies, Fremanezumab, Drugs, Medical specialties, RTT, Hepatotoxins, Clinical medicine, Amines, Immunosuppressants, Abacavir/dolutegravir/lamivudine, Solar urticaria

No new safety signals were identified in this population that were inconsistent with the known safety profile of AJOVY.

Key Points: 
  • No new safety signals were identified in this population that were inconsistent with the known safety profile of AJOVY.
  • Contraindications: AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients.
  • Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials.
  • Adverse Reactions: The most common adverse reactions (5% and greater than placebo) were injection site reactions.